Bachem (BANB.SW)

Executive Summary

Bachem Holding AG is a Swiss contract development and manufacturing organization (CDMO) specializing in peptides and oligonucleotides, with over 50 years of industry expertise. As a critical infrastructure partner for pharmaceutical and biotechnology companies, Bachem provides comprehensive development and GMP manufacturing services across clinical and commercial stages. The company's position is reinforced by its public listing on the SIX Swiss Exchange (ticker: BANB.SW) and a market capitalization of approximately CHF 6.5 billion. With a strong reputation in the TIDES space, Bachem benefits from the growing demand for peptide-based therapeutics, including GLP-1 receptor agonists and oligonucleotide therapies. Financially, Bachem has demonstrated robust revenue growth driven by its high-margin CDMO services and capacity expansions. However, near-term headwinds include destocking by certain customers and pricing pressure in generic peptides. The company's strategic focus on large-scale commercial manufacturing and early-stage development positions it well for long-term growth, supported by a healthy pipeline of drug candidates requiring its specialized capabilities. While valuation reflects the premium market for CDMO services, execution on capacity ramp-ups and customer wins remain key to sustaining investor confidence.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of a novel peptide therapy from a major pharma partner60% success
• Q2 2026Announcement of a multi-year manufacturing agreement for oligonucleotide drugs70% success
• Q2 2026Q2 2026 earnings report showing revenue acceleration from new capacity50% success